Roche Holding AG

Research Roche Holding AG (RO) on Bullrun: market cap CHF 299.27B, P/E 24.5, dividend yield 3.0%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CHF 299.27B; P/E is 24.5; dividend yield is 3.0%.

Peer valuation comparison

Latest P/E is 24.49x versus a Healthcare sector median of 24.46x.

Latest dividend yield is 2.95% versus a Healthcare sector median of 2.11% (39.8% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CHF 63.36BCHF 12.88BCHF 13.07B73.7%16.04CHF 5.58BCHF 33.19BCHF 33.80B
FY2024CHF 62.40BCHF 8.28BCHF 15.09B73.9%10.31CHF 6.98BCHF 36.35BCHF 31.77B
FY2023CHF 60.44BCHF 11.50BCHF 11.45B72.9%14.31CHF 5.38BCHF 30.78BCHF 29.32B
FY2022CHF 65.81BCHF 12.42BCHF 13.25B70.0%15.37CHF 4.99BCHF 26.54BCHF 27.99B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24CHF 299.27B24.52.6%9.8

Dividend history

Latest trailing dividend snapshot: annual dividend/share 9.8 CHF, yield 3.0%.

YearDividends/share
FY20259.7 CHF
FY20249.6 CHF
FY20239.5 CHF
FY20229.3 CHF
FY20219.1 CHF

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Roche Holding AG's market cap?

Roche Holding AG's market capitalization is CHF 299.27B.

What is Roche Holding AG's P/E ratio?

Roche Holding AG's price-to-earnings (P/E) ratio is 24.5.

Does Roche Holding AG pay a dividend?

Roche Holding AG has a dividend yield of 3.0%.

What does Roche Holding AG do?

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.